04:33 PM EDT, 07/03/2025 (MT Newswires) -- Innocan Pharma ( INNPF ) , at the close of trade Thursday said Ron Mayron resigned as Executive Chairman and a director of the company effective July 1, 2025.

A statement noted Mayron will remain with the company for three additional months as a special consultant. In his place, Iris Bincovich, a current director of the company, will be temporarily holding the position of Chair.

Innocan also announced "promising" results from its injectable delivery platform, LPT-CBD -- which utilizes liposome technology to deliver precise doses of synthetic cannabidiol (CBD) with controlled release -- after administration to Gottingen minipigs. The company said the study "demonstrates promising results of prolonged release and a favorable safety profile of CBD following a single subcutaneous administration of LPT-CBD in minipigs."

Innocan closed up $0.02 to $0.24 on the Canadian Securities Exchange.